FDA Patient-Focused Drug Development Meeting for Alopecia Areata- Drug Information Update
The Division of Drug Information (DDI)- serving the public by providing information on human drug products and drug product regulation by FDA.
On September 11, 2017, FDA is conducting a public meeting on Patient-Focused Drug Development for Alopecia Areata. The public meeting is intended to allow FDA to obtain patient perspectives on the impact of alopecia areata, including on daily life, patient views on treatment approaches, and decision factors taken into account when selecting a treatment.
For more information, please visit the FDA meeting website: Alopecia Areata.